Applied Therapeutics (NASDAQ:APLT) Posts Earnings Results

Applied Therapeutics (NASDAQ:APLT) posted its quarterly earnings data on Monday. The company reported ($0.24) earnings per share (EPS) for the quarter, Zacks reports.

Applied Therapeutics Stock Down 11.1 %

Shares of Applied Therapeutics stock opened at $0.33 on Wednesday. Applied Therapeutics has a 12 month low of $0.30 and a 12 month high of $10.62. The stock has a market cap of $38.19 million, a PE ratio of -0.20 and a beta of 1.88. The business has a fifty day simple moving average of $0.50 and a 200-day simple moving average of $3.21.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on APLT. William Blair cut shares of Applied Therapeutics from an “outperform” rating to a “market perform” rating in a report on Monday, December 23rd. Royal Bank of Canada decreased their target price on Applied Therapeutics from $4.00 to $1.50 and set a “sector perform” rating on the stock in a report on Friday, December 20th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Applied Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.10.

Applied Therapeutics Company Profile

Applied Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG.